Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4722950 | 0.89 | MAPT (0.58) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL612209 | 0.86 | MAPT (0.65) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17055144 | 0.82 | MAPT (0.63) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17054931 | 0.81 | MAPT (0.58) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17054792 | 0.79 | MAPT (0.68) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL23104629 | 0.79 | MAPT (0.56) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL18053971 | 0.79 | MAPT (0.56) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL29833754 | 0.79 | MAPT (0.56) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL25193029 | 0.79 | MAPT (0.56) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17055328 | 0.79 | MAPT (0.56) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818724-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107253963-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-04-14 | — | — | CN | disclosed |
| CN-110818724-A | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-8618107-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2566869-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | Gilead Connecticut, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | MAPT 2025/4885POLB 1645/4885RAB9A 4335/4885 |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | MAPT 2025/4885POLB 1645/4885RAB9A 4335/4885 |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | MAPT 2025/4885POLB 1645/4885RAB9A 4335/4885 |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | MAPT 2025/4885POLB 1645/4885RAB9A 4335/4885 |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | MAPT 2025/4885POLB 1645/4885RAB9A 4335/4885 |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPT 1236/4885POLB 1657/4885RAB9A 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.